Fluorodeoxyglucose positron emission tomography (FDG-PET) for the differential diagnosis of pancreatic lesions;Fluordeoxyglucose Positronenemissionstomographie (FDG-PET) zur Dignitätsbeurteilung von Läsionen des Pankreas

Chirurg

Volumn 72, Issue 9, 2001, Pages 989-994

  Zimny, M ^a   Schumpelick, V ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Chronic pancreatitis; Differential diagnosis; Fluorodeoxyglucose; Pancreatic carcinoma; Positron emission tomography

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CHRONIC DISEASE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; LYMPH NODE METASTASIS; MORTALITY; PANCREAS TUMOR; PANCREATITIS; PATIENT SELECTION; RADIOGRAPHY; REVIEW; ROC CURVE; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TIME;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; PANCREATIC NEOPLASMS; PANCREATITIS; PATIENT SELECTION; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0346977706     PISSN: 00094722     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00002602     Document Type: Article

References (43)

1. Bakkevold KE, Kambestad B (1993) Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater - the prognostic factors influencing the long-term results. A prospective multicentre study. Eur J Surg Oncol 19: 147
2. Bares R, Klever P, Hellwig D, Hauptmann S, et al (1993) Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results. Nucl Med Commun 14: 596
3. Bares R, Gehl HB, Kaiser HJ, Klever P, et al (1993) Magnetic resonance imaging (MRI) and positron emission tomography (PET) using fluorine-18 labelled deoxyglucose (FDG) for detection of pancreatic cancer: comparison and image merging. Eur J Nucl Med 20: 977
4. Bares R, Klever P, Hauptmann S, Hellwig D, et al (1994) F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192: 79
5. Bares R, Dohmen BM, Cremerius U, Fass J, et al (1996) Ergebnisse der Positronenemissiontomography mit Fluor-18-markierter Fluordeoxyglucose bei Differentialdiagnose und Staging des Pankreascarcinoms. Radiologe 36: 435
6. Benyounes H, Smith FW, Campbell C, Evans NT, et al (1995) Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma. Nucl Med Commun 16: 575
7. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP (1995) Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82: 111
8. Carter DC (1992) Cancer of the head of the pancreas or chronic pancreatitis? A diagnostic dilemma. Surgery 111: 602
9. Conlon KC, Klimstra DS, Brennan MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223: 273
10. Delbeke D, Rose DM, Chapman WC, Pinson CW, et al (1999) Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 40: 1784
11. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN (1998) FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39: 1030
12. Diederichs CG, Staib L, Glasbrenner B, Guhlmann A, et al (1999) F-18 fluorodeoxyglucose (FDG) and c-reactive proteine (CRP). Clin Positron Imaging 2: 131
13. Diederichs CG, Staib L, Vogel J, Glasbrenner B, et al (2000) Values and limitations of 18F-fluorodeoxyglucose-positronemission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 20: 109
14. Friess H, Langhans J, Ebert M, Beger HG, et al (1995) Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 36: 771
15. Fröhlich A, Diederichs CG, Staib L, Vogel J, et al (1999) Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 40: 250
16. Haberkorn U, Ziegler SI, Oberdorfer F, Trojan H, et al (1994) FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 21: 827
17. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, et al (1994) The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 35: 1308
18. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, et al (1998) FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 39: 1727
19. Ho CL, Dehdashti F, Griffeth LK, Buse PE, et al (1996) FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr 20: 363
20. Hustinx R, Smith RJ, Benard F, Rosenthal DI, et al (1999) Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 26: 1345
21. Imdahl A, Nitzsche E, Krautmann F, Hogerle S, et al (1999) Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 86: 194
22. Inokuma T, Tamaki N, Torizuka T, Magata Y, et al (1995) Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 195: 345
23. Kato T, Fukatsu H, Ito K, Tadokoro M, et al (1995) Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. Eur J Nucl Med 22: 32
24. Keogan MT, Tyler D, Clark L, Branch MS, et al (1998) Diagnosis of pancreatic carcinoma: role of FDG PET. Am J Roentgenol 171: 1565
25. Klever P, Bares R, Fass J, Büll U, Schumpelick V (1992) PET with fluorine-18 deoxyglucose for pancreatic disease. Lancet 340: 1158
26. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, et al (1999) Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 54: 248
27. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, et al (2000) Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 89: 2547
28. Nakata B, Chung YS, Nishimura S, Nishihara T, et al (1997) 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 79: 695
29. Rajput A, Stellato TA, Faulhaber PF, Vesselle HJ, Miraldi F (1998) The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease. Surgery 124: 793
30. Reske SN, Grillenberger KG, Glatting G, Port M, et al (1997) Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 38: 1344
31. Rose DM, Delbeke D, Beauchamp RD, Chapman WC, et al (1999) 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 229: 729
32. Rumstadt B, Trede M (1996) Chirurgische Therapie der Pankreaserkrankungen. Radiologe 36: 375
33. Sendler A, Avril N, Roder JD, Schwaiger M, Siewert JR (1998) Kann die Dignität von Pankreastumoren durch die Positronen-Emissions-Tomographie (PET) sicher genug beurteilt werden. Langenbecks Arch Chir 115 [Suppl Kongressband]: 1485
34. Sendler A, Avril N, Helmberger H, Stollfuss J, et al (2000) Preoperative evaluation of pancreatic masses with positron emission tomography using (18)F-fluorodeoxyglucose: diagnostic limitations. World J Surg 24: 1121
35. Shreve PD (1998) Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 25: 259
36. Stollfuss JC, Glatting G, Friess H, Kocher F, et al (1995) 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 195: 339
37. Strauss LG, Conti PS (1991) The applications of PET in clinical oncology. J Nucl Med 32: 623
38. Strauss LG (1996) Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med 23: 1409
39. Wagenknecht G, Kaiser HJ, Buell U (1999) Multimodale Integration, Korrelation und Fusion von Morphologie und Funktion: Methodik und erste klinische Anwendungen. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 170: 416
40. Warburg O (1956) On the origin of cancer cells. Science 123: 309
41. Zimny M, Bares R, Fass J, Adam G, et al (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24: 678
42. Zimny M, Buell U, Diederichs CG, Reske SN (1998) False-positive FDG PET in patients with pancreatic masses: an issue of proper patient selection? Eur J Nucl Med 25: 1352
43. Zimny M, Fass J, Bares R, Cremerius U, et al (2000) Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 35: 883